Diabetes, Metabolic Syndrome and Obesity (Nov 2024)

Cardiac Markers in Apparently Non-COVID-19 Individuals and Post-COVID-19 Individuals with and without Metabolic Syndrome, Trujillo-Peru 2023

  • Díaz-Ortega JL,
  • Otiniano NM,
  • Yupari-Azabache IL,
  • Alva Sevilla JM

Journal volume & issue
Vol. Volume 17
pp. 4307 – 4317

Abstract

Read online

Jorge Luis Díaz-Ortega,1 Nelida Milly Otiniano,2 Irma Luz Yupari-Azabache,2 Juan M Alva Sevilla3 1Escuela Profesional de Nutrición, Universidad César Vallejo, Trujillo, Perú; 2Institutos y Centros de Investigación, Universidad César Vallejo, Trujillo, Perú; 3Escuela Profesional de Medicina, Universidad César Vallejo, Trujillo, PerúCorrespondence: Jorge Luis Díaz-Ortega, Escuela Profesional de Nutrición, Universidad César Vallejo, Av. Larco 1770, Trujillo, 13001, Perú, Tel +51 944897194, Email [email protected]: To compare the levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in apparently non-COVID-19 (COVID-19-) and post-COVID-19 (COVID-19+) persons with metabolic syndrome (MetS+) and without metabolic syndrome (MetS-).Methods: The descriptive correlational study was carried out in 275 inhabitants of the city of Trujillo in 2023. Cardiac markers were determined by time-resolved immunofluorescence.Results: It was determined that 58.2% of the participants presented COVID-19 and 46.5% presented a diagnosis of MetS according to the harmonized ATP III criteria. Levels of cTnI greater than 0.05 ng/mL were found in low percentages in the COVID-19-/MetS-, COVID-19-/MetS+, and COVID-19+/MetS- groups at 0.7% each, and in the COVID-19+/SM+ group, it was 0.4%. NT-proBNP concentrations higher than 125 pg/mL were found in 2.9% of participants, of which 1.1% were in the COVID-19+/MetS+ group, a slightly higher proportion compared to the other groups.Conclusion: The proportion of individuals with normal or elevated cTnI and NT-ProBNP levels does not differ significantly in both healthy individuals, with MetS only, and those with mild Post COVID-19 with or without MetS; however, longitudinal studies are required to detect possible myocardial events in either group for adequate treatment, especially in those with COVID-19+/MetS+. Keywords: COVID-19, metabolic syndrome, troponin, natriuretic peptides

Keywords